O	0	19	Immunohistochemical	Immunohistochemical	JJ	B-NP
O	20	28	staining	staining	NN	I-NP
O	29	32	for	for	IN	B-PP
O	33	40	thyroid	thyroid	NN	B-NP
O	41	54	transcription	transcription	NN	I-NP
O	55	61	factor	factor	NN	I-NP
O	61	62	-	-	HYPH	B-NP
O	62	63	1	1	CD	I-NP
O	63	64	:	:	:	O
O	65	66	a	a	DT	B-NP
O	67	74	helpful	helpful	JJ	I-NP
O	75	78	aid	aid	NN	I-NP
O	79	81	in	in	IN	B-PP
O	82	92	discerning	discern	VBG	B-VP
O	93	100	primary	primary	JJ	B-NP
B-Multi-tissue_structure	101	105	site	site	NN	I-NP
O	106	108	of	of	IN	B-PP
B-Cancer	109	114	tumor	tumor	NN	B-NP
O	115	121	origin	origin	NN	I-NP
O	122	124	in	in	IN	B-PP
O	125	133	patients	patient	NNS	B-NP
O	134	138	with	with	IN	B-PP
B-Cancer	139	144	brain	brain	NN	B-NP
I-Cancer	145	155	metastases	metastasis	NNS	I-NP
O	155	156	.	.	.	O

B-Cancer	158	168	Metastatic	Metastatic	JJ	B-NP
I-Cancer	169	178	carcinoma	carcinoma	NN	I-NP
O	179	181	of	of	IN	B-PP
O	182	189	unknown	unknown	JJ	B-NP
O	190	197	primary	primary	JJ	I-NP
B-Multi-tissue_structure	198	204	origin	origin	NN	I-NP
O	205	207	is	be	VBZ	B-VP
O	208	209	a	a	DT	B-NP
O	210	220	perplexing	perplexing	JJ	I-NP
O	221	224	but	but	CC	I-NP
O	225	231	common	common	JJ	I-NP
O	232	239	problem	problem	NN	I-NP
O	239	240	,	,	,	O
O	241	251	accounting	account	VBG	B-VP
O	252	255	for	for	IN	B-PP
O	256	258	up	up	IN	B-NP
O	259	261	to	to	TO	I-NP
O	262	264	10	10	CD	I-NP
O	264	265	%	%	NN	I-NP
O	266	268	to	to	TO	I-NP
O	269	271	15	15	CD	I-NP
O	271	272	%	%	NN	I-NP
O	273	275	of	of	IN	B-PP
O	276	279	all	all	DT	B-NP
B-Cancer	280	285	solid	solid	JJ	I-NP
I-Cancer	286	292	tumors	tumor	NNS	I-NP
O	293	295	at	at	IN	B-PP
O	296	308	presentation	presentation	NN	B-NP
O	308	309	.	.	.	O

O	310	314	Many	Many	JJ	B-NP
O	315	317	of	of	IN	B-PP
O	318	323	these	these	DT	B-NP
B-Cancer	324	334	metastases	metastasis	NNS	I-NP
O	335	345	presumably	presumably	RB	B-ADVP
O	346	351	arise	arise	VBP	B-VP
O	352	356	from	from	IN	B-PP
B-Cancer	357	364	primary	primary	JJ	B-NP
I-Cancer	365	369	lung	lung	NN	I-NP
I-Cancer	370	380	carcinomas	carcinoma	NNS	I-NP
O	380	381	,	,	,	O
O	382	385	but	but	CC	O
O	386	389	the	the	DT	B-NP
O	390	401	morphologic	morphologic	JJ	I-NP
O	402	410	features	feature	NNS	I-NP
O	411	414	and	and	CC	O
O	415	434	immunohistochemical	immunohistochemical	JJ	B-NP
O	435	442	profile	profile	NN	I-NP
O	443	445	of	of	IN	B-PP
B-Cancer	446	450	lung	lung	NN	B-NP
I-Cancer	451	457	cancer	cancer	NN	I-NP
O	458	460	is	be	VBZ	B-VP
O	461	466	often	often	RB	B-ADVP
O	467	470	too	too	RB	B-ADJP
O	471	482	nonspecific	nonspecific	JJ	I-ADJP
O	483	485	to	to	TO	B-VP
O	486	492	permit	permit	VB	I-VP
O	493	504	unequivocal	unequivocal	JJ	B-NP
O	505	517	confirmation	confirmation	NN	I-NP
O	517	518	.	.	.	O

O	519	526	Thyroid	Thyroid	JJ	B-NP
O	527	540	transcription	transcription	NN	I-NP
O	541	547	factor	factor	NN	I-NP
O	547	548	-	-	HYPH	B-NP
O	548	549	1	1	CD	I-NP
O	550	551	(	(	(	O
O	551	554	TTF	TTF	NN	B-NP
O	554	555	-	-	HYPH	B-NP
O	555	556	1	1	CD	I-NP
O	556	557	)	)	)	O
O	558	560	is	be	VBZ	B-VP
O	561	570	expressed	express	VBN	I-VP
O	571	573	in	in	IN	B-PP
B-Cancer	574	578	lung	lung	NN	B-NP
I-Cancer	579	594	adenocarcinomas	adenocarcinoma	NNS	I-NP
O	595	598	and	and	CC	O
B-Cancer	599	606	thyroid	thyroid	JJ	B-NP
I-Cancer	607	617	carcinomas	carcinoma	NNS	I-NP
O	618	621	but	but	CC	B-PP
O	622	625	not	not	RB	B-PP
O	626	628	in	in	IN	I-PP
B-Cancer	629	644	adenocarcinomas	adenocarcinoma	NNS	B-NP
O	645	652	arising	arise	VBG	B-VP
O	653	657	from	from	IN	B-PP
O	658	663	other	other	JJ	B-NP
B-Multi-tissue_structure	664	669	sites	site	NNS	I-NP
O	669	670	.	.	.	O

O	671	674	For	For	IN	B-PP
O	675	683	patients	patient	NNS	B-NP
O	684	688	with	with	IN	B-PP
B-Cancer	689	704	adenocarcinomas	adenocarcinoma	NNS	B-NP
O	705	707	in	in	IN	B-PP
O	708	711	the	the	DT	B-NP
B-Organ	712	716	lung	lung	NN	I-NP
O	716	717	,	,	,	O
O	718	721	TTF	TTF	NN	B-NP
O	721	722	-	-	HYPH	B-NP
O	722	723	1	1	CD	I-NP
O	724	732	staining	staining	NN	I-NP
O	733	735	is	be	VBZ	B-VP
O	736	739	now	now	RB	B-ADVP
O	740	749	routinely	routinely	RB	B-VP
O	750	754	used	use	VBN	I-VP
O	755	757	to	to	TO	B-VP
O	758	769	distinguish	distinguish	VB	I-VP
O	770	771	a	a	DT	B-NP
B-Cancer	772	779	primary	primary	JJ	I-NP
I-Cancer	780	784	lung	lung	NN	I-NP
I-Cancer	785	791	cancer	cancer	NN	I-NP
O	792	796	from	from	IN	B-PP
O	797	798	a	a	DT	B-NP
B-Organ	799	803	lung	lung	NN	I-NP
O	804	814	metastasis	metastasis	NN	I-NP
O	814	815	.	.	.	O

O	816	821	Along	Along	IN	B-PP
O	822	827	these	these	DT	B-NP
O	828	832	same	same	JJ	I-NP
O	833	838	lines	line	NNS	I-NP
O	838	839	,	,	,	O
O	840	843	TTF	TTF	NN	B-NP
O	843	844	-	-	HYPH	B-NP
O	844	845	1	1	CD	I-NP
O	846	854	staining	staining	NN	I-NP
O	855	860	might	might	MD	B-VP
O	861	866	prove	prove	VB	I-VP
O	867	873	useful	useful	JJ	B-ADJP
O	874	876	in	in	IN	B-PP
O	877	887	localizing	localize	VBG	B-VP
O	888	891	the	the	DT	B-NP
B-Cancer	892	897	tumor	tumor	NN	I-NP
O	898	904	origin	origin	NN	I-NP
O	905	907	of	of	IN	B-PP
B-Cancer	908	923	adenocarcinomas	adenocarcinoma	NNS	B-NP
O	924	935	encountered	encounter	VBD	B-VP
O	936	943	outside	outside	RB	B-ADVP
O	944	946	of	of	IN	B-PP
O	947	950	the	the	DT	B-NP
B-Organ	951	955	lung	lung	NN	I-NP
O	955	956	.	.	.	O

O	957	960	The	The	DT	B-NP
O	961	969	archival	archival	JJ	I-NP
O	970	978	surgical	surgical	JJ	I-NP
O	979	988	pathology	pathology	NN	I-NP
O	989	994	files	file	NNS	I-NP
O	995	997	of	of	IN	B-PP
O	998	1001	The	The	DT	B-NP
O	1002	1007	Johns	Johns	NNP	I-NP
O	1008	1015	Hopkins	Hopkins	NNP	I-NP
O	1016	1024	Hospital	Hospital	NNP	I-NP
O	1025	1029	were	be	VBD	B-VP
O	1030	1038	searched	search	VBN	I-VP
O	1039	1042	for	for	IN	B-PP
O	1043	1048	cases	case	NNS	B-NP
O	1049	1051	of	of	IN	B-PP
B-Cancer	1052	1057	brain	brain	NN	B-NP
I-Cancer	1058	1068	metastases	metastasis	NNS	I-NP
O	1069	1077	biopsied	biopsie	VBD	B-VP
O	1078	1085	between	between	IN	B-PP
O	1086	1090	1990	1990	CD	B-NP
O	1091	1094	and	and	CC	I-NP
O	1095	1099	2000	2000	CD	I-NP
O	1099	1100	.	.	.	O

B-Tissue	1101	1107	Tissue	Tissue	NN	B-NP
I-Tissue	1108	1114	blocks	block	NNS	I-NP
O	1115	1119	were	be	VBD	B-VP
O	1120	1128	obtained	obtain	VBN	I-VP
O	1129	1132	and	and	CC	O
O	1133	1149	immunoperoxidase	immunoperoxidase	NN	B-NP
O	1150	1158	staining	staining	NN	I-NP
O	1159	1162	was	be	VBD	B-VP
O	1163	1172	performed	perform	VBN	I-VP
O	1173	1178	using	use	VBG	B-VP
O	1179	1182	the	the	DT	B-NP
O	1183	1186	TTF	TTF	NN	I-NP
O	1186	1187	-	-	HYPH	B-NP
O	1187	1188	1	1	CD	I-NP
O	1189	1197	antibody	antibody	NN	I-NP
O	1197	1198	.	.	.	O

O	1199	1202	The	The	DT	B-NP
O	1203	1210	medical	medical	JJ	I-NP
O	1211	1218	records	record	NNS	I-NP
O	1219	1223	were	be	VBD	B-VP
O	1224	1232	reviewed	review	VBN	I-VP
O	1233	1244	independent	independent	JJ	B-ADJP
O	1245	1247	of	of	IN	B-PP
O	1248	1251	the	the	DT	B-NP
O	1252	1260	staining	staining	NN	I-NP
O	1261	1268	results	result	VBZ	B-VP
O	1269	1271	to	to	TO	I-VP
O	1272	1281	determine	determine	VB	I-VP
B-Multi-tissue_structure	1282	1286	site	site	NN	B-NP
O	1287	1289	of	of	IN	B-PP
B-Cancer	1290	1295	tumor	tumor	NN	B-NP
O	1296	1302	origin	origin	NN	I-NP
O	1302	1303	.	.	.	O

O	1304	1311	Seventy	Seventy	CD	B-NP
O	1311	1312	-	-	HYPH	I-NP
O	1312	1316	five	five	CD	I-NP
O	1317	1325	patients	patient	NNS	I-NP
O	1326	1335	underwent	undergo	VBD	B-VP
O	1336	1344	biopsies	biopsy	NNS	B-NP
O	1345	1347	of	of	IN	B-PP
B-Cancer	1348	1358	carcinomas	carcinoma	NNS	B-NP
O	1359	1369	metastatic	metastatic	JJ	B-ADJP
O	1370	1372	to	to	TO	B-PP
O	1373	1376	the	the	DT	B-NP
B-Organ	1377	1382	brain	brain	NN	I-NP
O	1382	1383	.	.	.	O

O	1384	1386	At	At	IN	B-PP
O	1387	1390	the	the	DT	B-NP
O	1391	1395	time	time	NN	I-NP
O	1396	1398	of	of	IN	B-PP
B-Organ	1399	1404	brain	brain	NN	B-NP
O	1405	1411	biopsy	biopsy	NN	I-NP
O	1411	1412	,	,	,	O
O	1413	1416	the	the	DT	B-NP
O	1417	1424	primary	primary	JJ	I-NP
B-Multi-tissue_structure	1425	1429	site	site	NN	I-NP
O	1430	1432	of	of	IN	B-PP
B-Cancer	1433	1438	tumor	tumor	NN	B-NP
O	1439	1445	origin	origin	NN	I-NP
O	1446	1449	was	be	VBD	B-VP
O	1450	1455	known	know	VBN	I-VP
O	1456	1458	in	in	IN	B-PP
O	1459	1461	45	45	CD	B-NP
O	1462	1467	cases	case	NNS	I-NP
O	1468	1471	and	and	CC	O
O	1472	1479	unknown	unknown	JJ	B-ADJP
O	1480	1482	in	in	IN	B-PP
O	1483	1485	30	30	CD	B-NP
O	1486	1491	cases	case	NNS	I-NP
O	1491	1492	.	.	.	O

O	1493	1503	Ultimately	Ultimately	RB	B-ADVP
O	1503	1504	,	,	,	O
O	1505	1508	the	the	DT	B-NP
O	1509	1516	primary	primary	JJ	I-NP
B-Multi-tissue_structure	1517	1521	site	site	NN	I-NP
O	1522	1525	was	be	VBD	B-VP
O	1526	1537	established	establish	VBN	I-VP
O	1538	1540	on	on	IN	B-PP
O	1541	1549	clinical	clinical	JJ	B-NP
O	1550	1553	and	and	CC	I-NP
O	1554	1566	radiographic	radiographic	JJ	I-NP
O	1567	1574	grounds	ground	NNS	I-NP
O	1575	1577	in	in	IN	B-PP
O	1578	1580	71	71	CD	B-NP
O	1581	1586	cases	case	NNS	I-NP
O	1587	1588	(	(	(	O
O	1588	1590	95	95	CD	B-NP
O	1590	1591	%	%	NN	I-NP
O	1591	1592	)	)	)	O
O	1592	1593	.	.	.	O

O	1594	1599	These	These	DT	B-NP
O	1600	1608	included	include	VBD	B-VP
O	1609	1611	40	40	CD	B-NP
O	1612	1613	(	(	(	O
O	1613	1615	56	56	CD	B-NP
O	1615	1616	%	%	NN	I-NP
O	1616	1617	)	)	)	O
B-Cancer	1618	1628	metastases	metastasis	NNS	B-NP
O	1629	1633	from	from	IN	B-PP
O	1634	1635	a	a	DT	B-NP
B-Cancer	1636	1643	primary	primary	JJ	I-NP
I-Cancer	1644	1648	lung	lung	NN	I-NP
I-Cancer	1649	1658	carcinoma	carcinoma	NN	I-NP
O	1659	1662	and	and	CC	O
O	1663	1665	31	31	CD	B-NP
O	1666	1667	(	(	(	O
O	1667	1669	44	44	CD	B-NP
O	1669	1670	%	%	NN	I-NP
O	1670	1671	)	)	)	O
B-Cancer	1672	1682	metastases	metastasis	NNS	B-NP
O	1683	1687	from	from	IN	B-PP
O	1688	1692	some	some	DT	B-NP
B-Cancer	1693	1705	nonpulmonary	nonpulmonary	JJ	I-NP
I-Cancer	1706	1715	carcinoma	carcinoma	NN	I-NP
O	1715	1716	.	.	.	O

O	1717	1720	TTF	TTF	NN	B-NP
O	1720	1721	-	-	HYPH	B-NP
O	1721	1722	1	1	CD	I-NP
O	1723	1731	staining	staining	NN	I-NP
O	1732	1735	was	be	VBD	B-VP
O	1736	1743	present	present	JJ	B-ADJP
O	1744	1746	in	in	IN	B-PP
O	1747	1749	31	31	CD	B-NP
O	1750	1752	of	of	IN	B-PP
O	1753	1756	the	the	DT	B-NP
O	1757	1759	40	40	CD	I-NP
O	1760	1761	(	(	(	O
O	1761	1763	78	78	CD	B-NP
O	1763	1764	%	%	NN	I-NP
O	1764	1765	)	)	)	O
B-Cancer	1766	1776	metastatic	metastatic	JJ	B-NP
I-Cancer	1777	1781	lung	lung	NN	I-NP
I-Cancer	1782	1792	carcinomas	carcinoma	NNS	I-NP
O	1792	1793	,	,	,	O
O	1794	1797	but	but	CC	O
O	1798	1800	in	in	IN	B-PP
O	1801	1805	only	only	RB	B-NP
O	1806	1807	1	1	CD	I-NP
O	1808	1810	of	of	IN	B-PP
O	1811	1814	the	the	DT	B-NP
O	1815	1817	31	31	CD	I-NP
O	1818	1819	(	(	(	O
O	1819	1820	3	3	CD	B-NP
O	1820	1821	%	%	NN	I-NP
O	1821	1822	)	)	)	I-NP
B-Cancer	1823	1833	metastatic	metastatic	JJ	I-NP
I-Cancer	1834	1846	nonpulmonary	nonpulmonary	JJ	I-NP
I-Cancer	1847	1857	carcinomas	carcinoma	NNS	I-NP
O	1858	1859	(	(	(	O
O	1859	1860	a	a	DT	B-NP
B-Cancer	1861	1866	small	small	JJ	I-NP
I-Cancer	1866	1867	-	-	HYPH	I-NP
I-Cancer	1867	1871	cell	cell	NN	I-NP
I-Cancer	1872	1881	carcinoma	carcinoma	NN	I-NP
O	1882	1884	of	of	IN	B-PP
O	1885	1888	the	the	DT	B-NP
B-Organism_subdivision	1889	1898	sinonasal	sinonasal	JJ	I-NP
I-Organism_subdivision	1899	1904	tract	tract	NN	I-NP
O	1904	1905	)	)	)	O
O	1905	1906	.	.	.	O

O	1907	1911	When	When	WRB	B-ADVP
O	1912	1915	the	the	DT	B-NP
B-Cancer	1916	1926	metastatic	metastatic	JJ	I-NP
I-Cancer	1927	1931	lung	lung	NN	I-NP
I-Cancer	1932	1942	carcinomas	carcinoma	NNS	I-NP
O	1943	1947	were	be	VBD	B-VP
O	1948	1956	subtyped	subtype	VBN	I-VP
O	1956	1957	,	,	,	O
O	1958	1961	TTF	TTF	NN	B-NP
O	1961	1962	-	-	HYPH	B-NP
O	1962	1963	1	1	CD	I-NP
O	1964	1972	staining	staining	NN	I-NP
O	1973	1976	was	be	VBD	B-VP
O	1977	1982	noted	note	VBN	I-VP
O	1983	1985	in	in	IN	B-PP
O	1986	1988	11	11	CD	B-NP
O	1989	1991	of	of	IN	B-PP
O	1992	1994	11	11	CD	B-NP
O	1995	1996	(	(	(	O
O	1996	1999	100	100	CD	B-NP
O	1999	2000	%	%	NN	I-NP
O	2000	2001	)	)	)	O
B-Cancer	2002	2017	adenocarcinomas	adenocarcinoma	NNS	B-NP
O	2017	2018	,	,	,	O
O	2019	2021	in	in	IN	B-PP
O	2022	2023	6	6	CD	B-NP
O	2024	2026	of	of	IN	B-PP
O	2027	2028	7	7	CD	B-NP
O	2029	2030	(	(	(	O
O	2030	2032	86	86	CD	B-NP
O	2032	2033	%	%	NN	I-NP
O	2033	2034	)	)	)	O
B-Cancer	2035	2040	small	small	JJ	B-NP
I-Cancer	2040	2041	-	-	HYPH	I-NP
I-Cancer	2041	2045	cell	cell	NN	I-NP
I-Cancer	2046	2056	carcinomas	carcinoma	NNS	I-NP
O	2056	2057	,	,	,	O
O	2058	2060	in	in	IN	B-PP
O	2061	2063	15	15	CD	B-NP
O	2064	2066	of	of	IN	B-PP
O	2067	2069	19	19	CD	B-NP
O	2070	2071	(	(	(	O
O	2071	2073	79	79	CD	B-NP
O	2073	2074	%	%	NN	I-NP
O	2074	2075	)	)	)	O
B-Cancer	2076	2081	large	large	JJ	B-NP
I-Cancer	2081	2082	-	-	HYPH	I-NP
I-Cancer	2082	2086	cell	cell	NN	I-NP
I-Cancer	2087	2097	carcinomas	carcinoma	NNS	I-NP
O	2097	2098	,	,	,	O
O	2099	2102	and	and	CC	O
O	2103	2105	in	in	IN	B-PP
O	2106	2110	none	none	NN	B-NP
O	2111	2113	of	of	IN	B-PP
O	2114	2115	3	3	CD	B-NP
O	2116	2117	(	(	(	O
O	2117	2118	0	0	CD	B-NP
O	2118	2119	%	%	NN	I-NP
O	2119	2120	)	)	)	O
B-Cancer	2121	2129	squamous	squamous	JJ	B-NP
I-Cancer	2130	2134	cell	cell	NN	I-NP
I-Cancer	2135	2145	carcinomas	carcinoma	NNS	I-NP
O	2145	2146	.	.	.	O

O	2147	2150	TTF	TTF	NN	B-NP
O	2150	2151	-	-	HYPH	B-NP
O	2151	2152	1	1	CD	I-NP
O	2153	2161	staining	staining	NN	I-NP
O	2162	2164	is	be	VBZ	B-VP
O	2165	2169	very	very	RB	B-ADJP
O	2170	2178	reliable	reliable	JJ	I-ADJP
O	2179	2181	in	in	IN	B-PP
O	2182	2192	discerning	discern	VBG	B-VP
O	2193	2200	whether	whether	IN	B-SBAR
O	2201	2202	a	a	DT	B-NP
B-Organ	2203	2208	brain	brain	NN	I-NP
O	2209	2219	metastasis	metastasis	NN	I-NP
O	2220	2223	has	have	VBZ	B-VP
O	2224	2230	arisen	arise	VBN	I-VP
O	2231	2235	from	from	IN	B-PP
O	2236	2237	a	a	DT	B-NP
B-Multi-tissue_structure	2238	2247	pulmonary	pulmonary	JJ	I-NP
O	2248	2250	or	or	CC	I-NP
B-Multi-tissue_structure	2251	2263	nonpulmonary	nonpulmonary	JJ	I-NP
I-Multi-tissue_structure	2264	2268	site	site	NN	I-NP
O	2268	2269	,	,	,	O
O	2270	2282	particularly	particularly	RB	B-ADVP
O	2283	2287	when	when	WRB	B-ADVP
O	2288	2295	dealing	deal	VBG	B-VP
O	2296	2300	with	with	IN	B-PP
B-Cancer	2301	2316	adenocarcinomas	adenocarcinoma	NNS	B-NP
O	2317	2320	and	and	CC	O
B-Cancer	2321	2326	large	large	JJ	B-NP
I-Cancer	2326	2327	-	-	HYPH	I-NP
I-Cancer	2327	2331	cell	cell	NN	I-NP
I-Cancer	2332	2342	carcinomas	carcinoma	NNS	I-NP
O	2342	2343	.	.	.	O

O	2344	2347	TTF	TTF	NN	B-NP
O	2347	2348	-	-	HYPH	O
O	2348	2349	1	1	CD	B-NP
O	2350	2370	immunohistochemistry	immunohistochemistry	NN	I-NP
O	2371	2376	could	could	MD	B-VP
O	2377	2382	focus	focus	VB	I-VP
O	2383	2386	the	the	DT	B-NP
O	2387	2393	search	search	NN	I-NP
O	2394	2397	for	for	IN	B-PP
O	2398	2401	the	the	DT	B-NP
B-Cancer	2402	2409	primary	primary	JJ	I-NP
I-Cancer	2410	2415	tumor	tumor	NN	I-NP
O	2416	2419	for	for	IN	B-PP
O	2420	2428	patients	patient	NNS	B-NP
O	2429	2439	presenting	present	VBG	B-VP
O	2440	2444	with	with	IN	B-PP
B-Organ	2445	2450	brain	brain	NN	B-NP
O	2451	2461	metastasis	metastasis	NN	I-NP
O	2462	2464	as	as	IN	B-PP
O	2465	2468	the	the	DT	B-NP
O	2469	2476	initial	initial	JJ	I-NP
O	2477	2490	manifestation	manifestation	NN	I-NP
O	2490	2491	.	.	.	O

